Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Published:2015-09-04 Issue:24 Volume:21 Page:5469-5479
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Peeters Marc,Oliner Kelly S.,Price Timothy J.,Cervantes Andrés,Sobrero Alberto F.,Ducreux Michel,Hotko Yevhen,André Thierry,Chan Emily,Lordick Florian,Punt Cornelis J.A.,Strickland Andrew H.,Wilson Gregory,Ciuleanu Tudor E.,Roman Laslo,Van Cutsem Eric,He Pei,Yu Hua,Koukakis Reija,Terwey Jan-Henrik,Jung Andre S.,Sidhu Roger,Patterson Scott D.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis;Frontiers in Oncology;2024-07-10

2. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

3. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-06

4. Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review;Diseases;2024-04-20

5. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC;Journal of Oncology Pharmacy Practice;2024-04-13